Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Complexity of sortilin
View:
Post by jfm1330 on Jul 18, 2022 5:38pm

Complexity of sortilin

If you want to freak out about how complex the sortilin role can be, and how it can change from cell types, and even within the same cell type, read this very recent article published this year. Sortiln has over 50 possible ligands, and depending on the ligand, then the pathway within the cell can vary. Reading this article, it seems pretty clear that all sortilin expression is not the same and does not behave in the same way. In the context of TH1902, the big question that comes to mind is how sortilin in cancer cells compare to sortilin in healthy cells, and as I said, in healthy cells, the behavior of sortilin, so can it also vary from in cancer cells from on cancer type to another, and even within a cancer type depending on how advanced the cancer is. For example, is it the same in metastatic cancer as in non metastatic cancer? This article does not talk about cancer, it is focused on sortilin role in metabolism, but it is interesting to have an understanding of how complex the role of this receptor is. In the context of the recent press release about the grant to better understand the fate of TH1902 in TNBC, you can see that it will be a big task just to understand some aspect of it.

https://www.sciencedirect.com/science/article/pii/S0022227522000761
Comment by jeffm34 on Jul 18, 2022 7:03pm
There is a short mention about cancer in the article. Several groups have used AF38469 in biological experiments. As previously discussed, Rhost et al. discovered that sortilin-mediated endocytosis of progranulin is required for progranulin to induce metastasis of breast cancer cells. Delivery of AF38469 into MDA-MB-231 human breast cancer cell-xenografted mice via their drinking water ...more  
Comment by Wino115 on Jul 18, 2022 7:23pm
Rhost is one of the Univ of Gothenburg researchers who are the other sortilin focused group. They are solely focusing on TNBC and using sort1 to degrade cancer stem cells.  She is now the CEO of the early stage Venture cap company they started and we've peaked at. FYI, I did an extensive search 4 months ago to see if I could find anything on quantitatively derived genetic expressions ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities